HCM
Price
$16.45
Change
+$0.58 (+3.65%)
Updated
Aug 15 closing price
Capitalization
2.73B
89 days until earnings call
OGI
Price
$1.43
Change
-$0.13 (-8.33%)
Updated
Aug 15 closing price
Capitalization
195.86M
Interact to see
Advertisement

HCM vs OGI

Header iconHCM vs OGI Comparison
Open Charts HCM vs OGIBanner chart's image
HUTCHMED (China)
Price$16.45
Change+$0.58 (+3.65%)
Volume$34.06K
Capitalization2.73B
Organigram Global
Price$1.43
Change-$0.13 (-8.33%)
Volume$1.07M
Capitalization195.86M
HCM vs OGI Comparison Chart in %
Loading...
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HCM vs. OGI commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCM is a Hold and OGI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (HCM: $16.45 vs. OGI: $1.43)
Brand notoriety: HCM and OGI are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HCM: 56% vs. OGI: 143%
Market capitalization -- HCM: $2.73B vs. OGI: $195.86M
HCM [@Pharmaceuticals: Generic] is valued at $2.73B. OGI’s [@Pharmaceuticals: Generic] market capitalization is $195.86M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HCM’s FA Score shows that 0 FA rating(s) are green whileOGI’s FA Score has 1 green FA rating(s).

  • HCM’s FA Score: 0 green, 5 red.
  • OGI’s FA Score: 1 green, 4 red.
According to our system of comparison, OGI is a better buy in the long-term than HCM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HCM’s TA Score shows that 5 TA indicator(s) are bullish while OGI’s TA Score has 7 bullish TA indicator(s).

  • HCM’s TA Score: 5 bullish, 6 bearish.
  • OGI’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, OGI is a better buy in the short-term than HCM.

Price Growth

HCM (@Pharmaceuticals: Generic) experienced а +9.67% price change this week, while OGI (@Pharmaceuticals: Generic) price change was -1.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

HCM is expected to report earnings on Nov 14, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HCM($2.73B) has a higher market cap than OGI($196M). OGI has higher P/E ratio than HCM: OGI (163.90) vs HCM (6.21). HCM YTD gains are higher at: 14.157 vs. OGI (-11.180). HCM has higher annual earnings (EBITDA): 14.1M vs. OGI (-5.23M). HCM has more cash in the bank: 836M vs. OGI (14.1M). OGI has less debt than HCM: OGI (9.54M) vs HCM (89.8M). HCM has higher revenues than OGI: HCM (630M) vs OGI (194M).
HCMOGIHCM / OGI
Capitalization2.73B196M1,393%
EBITDA14.1M-5.23M-270%
Gain YTD14.157-11.180-127%
P/E Ratio6.21163.904%
Revenue630M194M325%
Total Cash836M14.1M5,929%
Total Debt89.8M9.54M942%
FUNDAMENTALS RATINGS
HCM vs OGI: Fundamental Ratings
HCM
OGI
OUTLOOK RATING
1..100
6110
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7384
PRICE GROWTH RATING
1..100
5347
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OGI's Valuation (87) in the null industry is in the same range as HCM (88) in the Pharmaceuticals Major industry. This means that OGI’s stock grew similarly to HCM’s over the last 12 months.

OGI's Profit vs Risk Rating (100) in the null industry is in the same range as HCM (100) in the Pharmaceuticals Major industry. This means that OGI’s stock grew similarly to HCM’s over the last 12 months.

HCM's SMR Rating (73) in the Pharmaceuticals Major industry is in the same range as OGI (84) in the null industry. This means that HCM’s stock grew similarly to OGI’s over the last 12 months.

OGI's Price Growth Rating (47) in the null industry is in the same range as HCM (53) in the Pharmaceuticals Major industry. This means that OGI’s stock grew similarly to HCM’s over the last 12 months.

OGI's P/E Growth Rating (1) in the null industry is significantly better than the same rating for HCM (100) in the Pharmaceuticals Major industry. This means that OGI’s stock grew significantly faster than HCM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HCMOGI
RSI
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 20 days ago
73%
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
81%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VRREX18.330.10
+0.55%
Virtus Duff & Phelps Real Estate Secs R6
QUASX62.850.05
+0.08%
AB Small Cap Growth A
SZCAX50.57-0.08
-0.16%
DWS Small Cap Core A
JRAIX96.55-0.25
-0.26%
Janus Henderson Research I
BMPEX27.72-0.09
-0.32%
Beck Mack + Oliver Partners

HCM and

Correlation & Price change

A.I.dvisor tells us that HCM and CGC have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HCM and CGC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HCM
1D Price
Change %
HCM100%
+3.65%
CGC - HCM
23%
Poorly correlated
-12.75%
OGI - HCM
22%
Poorly correlated
-8.33%
CRON - HCM
22%
Poorly correlated
-5.95%
AQST - HCM
22%
Poorly correlated
N/A
KNSA - HCM
22%
Poorly correlated
+0.30%
More

OGI and

Correlation & Price change

A.I.dvisor indicates that over the last year, OGI has been loosely correlated with ACB. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if OGI jumps, then ACB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OGI
1D Price
Change %
OGI100%
-8.33%
ACB - OGI
61%
Loosely correlated
-5.75%
CGC - OGI
60%
Loosely correlated
-12.75%
CRON - OGI
60%
Loosely correlated
-5.95%
TLRY - OGI
57%
Loosely correlated
-12.71%
HROW - OGI
35%
Loosely correlated
-2.97%
More